Delcath Systems (Delcath Systems) Accounts Receivable

: $0.24 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Delcath Systems's accounts receivables for the quarter that ended in Dec. 2023 was $0.24 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Delcath Systems's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 40.80.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Delcath Systems's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $0.50.

Delcath Systems Accounts Receivable Historical Data

The historical data trend for Delcath Systems's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Delcath Systems Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

0.02

0.06

0.04

0.37

0.24

Delcath Systems Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Receivable																0.37	0.46	0.13	0.21	0.24

Delcath Systems Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Delcath Systems Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Delcath Systems's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.241	/	0.539	*	91
=	40.80

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Delcath Systems's accounts receivable are only considered to be worth 75% of book value:

Delcath Systems's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(32.454	+	0.75 * 0.241	+	0.5 * 3.322	-	22.836
-	0	-	0)	/	22.7616
=	0.50

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Delcath Systems Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Delcath Systems's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Delcath Systems (Delcath Systems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (NAS:DCTH) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

DV3R:Germany

Address

1633 Broadway, Suite 22C, New York, NY, USA, 10019

Website

https://www.delcath.com

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Executives

Vojo Vukovic	officer: See Remarks	C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Gerard J Michel	director, officer: Chief Executive Officer	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Sandra Pennell	officer: See Remarks	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
David L. Hoffman	officer: See Remarks	C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
John Purpura	officer: EVP, Regulatory Affairs	600 FIFTH AVENUE, 23RD FLOOR, NEW YORK NY 10020
John Richard Sylvester	director	C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Salamon Steven A J	director	25 ADMIRAL ROAD, TORONTO A6 M5R 2L4
Rosalind Advisors, Inc.	director, other: See Remarks	15 WELLESLEY STREET WEST, SUITE 326, TORONTO A6 M4Y 0G7
Kevin Muir	officer: See Remarks	C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Anthony Dias	officer: Vice President of Finance	C/O SEACHANGE INTERNATIONAL, 50 NAGOG PARK, ACTON MA 01720
Gil Aharon	director	15 WELLESLEY STREET WEST, SUITE 326, TORONTO A6 M4Y 0G7
Johnny John	officer: See Remarks	C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Elizabeth Czerepak	director	201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Christine Padula	officer: See Remarks	C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Simon Pedder	director	1001 MAIN STREET, SUITE 600, BUFFALO NY 14203